Unaudited Condensed Consolidated Statements of Changes in Stockholders' Equity - USD ($) $ in Thousands	Total	October 2025 Share Repurchase Program - Put Option	Common stock	Common stock October 2025 Share Repurchase Program - Put Option	Additional paid-in capital	Additional paid-in capital October 2025 Share Repurchase Program - Put Option	Accumulated other comprehensive income (loss)	Accumulated deficit
Beginning balance (in shares) at Dec. 31, 2024			112,550,156
Beginning balance at Dec. 31, 2024	$ 455,656		$ 113		$ 1,193,022		$ 2,676	$ (740,155)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense	32,255				32,255
Common stock issued under employee stock plans (in shares)			1,808,876
Common stock issued under employee stock plans	7,163		$ 2		7,161
Taxes related to net share settlement of equity awards	(26,447)				(26,447)
Repurchase of common stock (in shares)			(1,476,456)
Repurchase of common stock	(61,264)		$ (2)		(61,262)
Unrealized loss on derivative instruments, net of tax	(6,231)						(6,231)
Unrealized income (loss) on available for sale securities, net of tax	2,393						2,393
Common stock issued for debt conversion (in shares)			32
Common stock issued for debt conversion	1				1
Net loss	(35,783)							(35,783)
Ending balance (in shares) at Mar. 31, 2025			112,882,608
Ending balance at Mar. 31, 2025	367,743		$ 113		1,144,730		(1,162)	(775,938)
Beginning balance (in shares) at Dec. 31, 2025			117,546,852
Beginning balance at Dec. 31, 2025	598,656		$ 118		1,444,885		23,132	(869,479)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense	33,739				33,739
Common stock issued under employee stock plans (in shares)			2,622,743
Common stock issued under employee stock plans	7,970		$ 2		7,968
Taxes related to net share settlement of equity awards	(17,386)				(17,386)
Repurchase of common stock (in shares)			(4,429,520)	(925,925)
Repurchase of common stock	(110,000)	$ (20,009)	$ (4)	$ (1)	(109,996)	$ (20,008)
Unrealized loss on derivative instruments, net of tax	(952)						(952)
Unrealized income (loss) on available for sale securities, net of tax	(1,651)						(1,651)
Net loss	(36,854)							(36,854)
Ending balance (in shares) at Mar. 31, 2026			114,814,150
Ending balance at Mar. 31, 2026	$ 453,513		$ 115		$ 1,339,202		$ 20,529	$ (906,333)